A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Conditions: CLL/SLL Interventions: Drug: Lisaftoclax (APG-2575); Drug: Acalabrutinib; Drug: Fludarabine; Drug: Cyclophosphamide ，CTX; Drug: Rituximab; Drug: Chlorambucil Sponsors: Ascentage Pharma Group Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials